Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...

Dr. Maya Green discusses HIV prevention, addressing racial disparities in healthcare, and the powerful impact of stigma on ...

Federal datasets began disappearing from public view on Jan 31, in response to executive orders from President Donald Trump.

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application submissions for lenacapavir for human immunodeficiency virus (HIV) prevention.

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...

In a report this week, UNAIDS said at least 55 countries around the world had reported funding cuts to HIV programmes, including several in African countries. That included halts to 55 HIV projects ...

The Trump administration announced last week that it was cancelling nearly 10,000 foreign aid grants and contracts worth ...

Here’s what to know about how aid cuts to HIV/AIDS programmes are affecting African countries: Schoolgirls pass a mobile clinic, background, run by the Reproductive Health and HIV Institute (RHI ...

In HIV-1-infected patients with extensive drug resistance, the optimization of background antiretroviral therapy is essential when changing drugs after treatment failure. The genotypic sensitivity ...

After lenacapavir last year delivered a 96% reduction in HIV infections compared with background HIV incidence in one study—and previously showed 100% efficacy in another—the company is ...